Comparative Pharmacology
Head-to-head clinical analysis: CHLOROPROCAINE HYDROCHLORIDE versus LIDOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROPROCAINE HYDROCHLORIDE versus LIDOPEN.
CHLOROPROCAINE HYDROCHLORIDE vs LIDOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks voltage-gated sodium channels in nerve cell membranes, inhibiting conduction of nerve impulses. Exhibits rapid onset and short duration due to hydrolysis by plasma pseudocholinesterase.
Lidocaine is a sodium channel blocker, stabilizing neuronal membranes by inhibiting the influx of sodium ions, thereby preventing the propagation of action potentials and producing local anesthesia.
10-30 mL of 1% solution infiltrated locally; epidural: 15-25 mL of 2% or 3% solution, repeated as needed, not to exceed 800 mg total dose.
Lidocaine 2% topical gel: Apply 1-2 grams (approximately 5-10 cm ribbon) to affected area every 4-6 hours as needed, not to exceed 5 grams per day. For infiltration anesthesia: 1% solution, 0.5-5 mL injected locally; maximum 4.5 mg/kg.
None Documented
None Documented
Terminal elimination half-life of chloroprocaine is approximately 0.1-0.2 hours (6-12 minutes) in adults with normal pseudocholinesterase activity. This extremely short half-life accounts for its rapid clearance and short duration of action.
1.5–2 hours (terminal); prolonged in hepatic impairment
Primarily renal excretion of metabolites; unchanged drug undergoes rapid hydrolysis by plasma pseudocholinesterase, producing 2-chloro-4-aminobenzoic acid and diethylaminoethanol. Less than 2% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Renal (10% unchanged; 80% as metabolites), biliary/fecal (10%)
Category C
Category C
Local Anesthetic
Local Anesthetic